Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1)

RCT found addition of andecaliximab to modified oxaliplatin, leucovorin, and fluorouracil (mFOLFOX6) did not improve survival vs placebo (n=432; overall survival, 12.5 vs 11.8 months; progression free survival 7.5 vs 7.1 months).

Journal of Clinical Oncology